BIOMAT Database Logo BIOMAT Database Logo

A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. 1990

M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Department of Medical Chemistry, University of Helsinki, Finland.

Four women used vaginal rings releasing the synthetic progestin ST-1435 and ethinyl estradiol for at least three 21-day cycles with a 7-day treatment-free period between intervals of use. Patterns of bleeding were evaluated and serum concentrations of ST-1435, estradiol, progesterone and ethinyl estradiol were measured by radioimmunoassay. Total serum cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides and serum chemistry were determined before ring use and during the first and third treatment cycles. The women experienced no difficulties in using the vaginal ring and all continued to use the ring after the first three cycles. Bleeding control was good and hormonal side effects were minimal. Serum steroid concentrations were: ST-1435, 289 +/- 117 pmol/l (mean +/- SD); ethinyl estradiol, 172 +/- 108 pmol/l; and estradiol, 184 +/- 107 pmol/l. Concentrations of serum progesterone were low, indicating complete suppression of ovulation during treatment. Total serum cholesterol increased slightly during use of ring. However, this increase could be accounted for by an increase in serum HDL-cholesterol. Liver function tests were in the normal range during ring use and values of serum chemistry showed no significant changes. This contraceptive vaginal ring presents a good method of contraception, showing good bleeding control and no harmful metabolic effects.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008598 Menstruation The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
D008903 Minerals Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Mineral
D009652 Norpregnenes Pregnenes with one double bond or more than three double bonds which have undergone ring contractions or are lacking carbon-18 or carbon-19..
D009653 Norprogesterones Progesterones which have undergone ring contraction or which are lacking carbon 18 or 19.
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D003274 Contraceptive Devices, Female Contraceptive devices used by females. Cervical Cap,Coiled Spring,Vaginal Diaphragm,Vaginal Rings,Vaginal Shield,Vaginal Sponge,Cap, Cervical,Caps, Cervical,Cervical Caps,Coiled Springs,Contraceptive Device, Female,Device, Female Contraceptive,Devices, Female Contraceptive,Diaphragm, Vaginal,Diaphragms, Vaginal,Female Contraceptive Device,Female Contraceptive Devices,Ring, Vaginal,Rings, Vaginal,Shield, Vaginal,Shields, Vaginal,Sponge, Vaginal,Sponges, Vaginal,Spring, Coiled,Springs, Coiled,Vaginal Diaphragms,Vaginal Ring,Vaginal Shields,Vaginal Sponges
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot

Related Publications

M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST 1435.
November 1992, Obstetrics and gynecology,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol.
December 1994, Contraception,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
August 2007, Expert opinion on pharmacotherapy,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol.
July 1979, Contraception,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
January 1984, Upsala journal of medical sciences,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol.
March 2002, American journal of obstetrics and gynecology,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.
November 1990, Contraception,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
January 2006, Fertility and sterility,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.
December 1994, Contraception,
M Laurikka-Routti, and M Haukkamaa, and O Heikinheimo
Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
July 2005, Contraception,
Copied contents to your clipboard!